| Dexamethasone in hospitalized patients with Covid-19. P Horby, WS Lim, JR Emberson, M Mafham, JL Bell, L Linsell, N Staplin, ... N Engl J Med, 693-704, 2021 | 7111* | 2021 |
| A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19 B Cao, Y Wang, D Wen, W Liu, J Wang, G Fan, L Ruan, B Song, Y Cai, ... New England Journal of Medicine, 2020 | 5833 | 2020 |
| Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Y Wang, D Zhang, G Du, R Du, J Zhao, Y Jin, S Fu, L Gao, Z Cheng, Q Lu, ... The Lancet 395 (10236), 1569-1578, 2020 | 3597 | 2020 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 397 (10285), 1637-1645, 2021 | 1358* | 2021 |
| Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. P Horby, M Mafham, L Linsell, JL Bell, N Staplin, JR Emberson, M Wiselka, ... The New England journal of medicine, 2020 | 1254 | 2020 |
| Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, M Mafham, JL Bell, L Linsell, N Staplin, J Emberson, ... The Lancet 396 (10259), 1345-1352, 2020 | 646 | 2020 |
| Adaptive designs in clinical trials: why use them, and how to run and report them P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ... BMC medicine 16 (1), 1-15, 2018 | 388 | 2018 |
| Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, A Roddick, E Spata, N Staplin, J Emberson, G Pessoa-Amorim, ... Lancet 397 (10274), 605-612, 2021 | 268 | 2021 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, G Pessoa-Amorim, N Staplin, JR Emberson, M Campbell, ... Lancet 399 (10320), 143-151, 2022 | 190* | 2022 |
| Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial PW Horby, L Estcourt, L Peto, JR Emberson, N Staplin, E Spata, ... Lancet 397 (10289), 2049-2059, 2021 | 176 | 2021 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet, 2021 | 150 | 2021 |
| A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection D Magirr, T Jaki, J Whitehead Biometrika 99 (2), 494-501, 2012 | 135 | 2012 |
| Probabilistic relabelling strategies for the label switching problem in Bayesian mixture models M Sperrin, T Jaki, E Wit Statistics and Computing 20 (3), 357-366, 2010 | 116 | 2010 |
| Assessing differential effects: Applying regression mixture models to identify variations in the influence of family resources on academic achievement. ML Van Horn, T Jaki, K Masyn, SL Ramey, JA Smith, S Antaramian Developmental psychology 45 (5), 1298, 2009 | 109 | 2009 |
| A review of statistical updating methods for clinical prediction models TL Su, T Jaki, GL Hickey, I Buchan, M Sperrin Statistical methods in medical research 27 (1), 185-197, 2018 | 105 | 2018 |
| Optimal design of multi‐arm multi‐stage trials J Wason, T Jaki Statistics in Medicine 31 (30), 4269-4279, 2012 | 103 | 2012 |
| Some recommendations for multi-arm multi-stage trials J Wason, D Magirr, M Law, T Jaki Statistical methods in medical research 25 (2), 716-727, 2016 | 84 | 2016 |
| Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group The Lancet Respiratory Medicine 9 (12), 1419-1426, 2021 | 82 | 2021 |
| Differential effects of parental controls on adolescent substance use: For whom is the family most important? AA Fagan, ML Van Horn, J David Hawkins, T Jaki Journal of quantitative criminology 29, 347-368, 2013 | 78 | 2013 |
| Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study SH Khoo, R Fitzgerald, T Fletcher, S Ewings, T Jaki, R Lyon, N Downs, ... Journal of Antimicrobial Chemotherapy, 2021 | 77 | 2021 |
Philip PallmannCardiff University, UKVerified email at cardiff.ac.uk
